{"id":"4-demethyl-4-cholestryloxycarbonylpenclomedine","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Myelosuppression"},{"rate":"10-30%","effect":"Nausea and vomiting"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-15%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This inhibition leads to DNA damage and ultimately cell death in rapidly dividing cancer cells. The exact mechanism of action is not fully understood, but it is thought to involve the formation of DNA-protein crosslinks and the activation of apoptosis pathways.","oneSentence":"4-Demethyl-4-cholestryloxycarbonylpenclomedine is a chemotherapy medication that works by inhibiting the enzyme topoisomerase II.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:19:41.352Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer"},{"name":"Metastatic ovarian cancer"}]},"trialDetails":[{"nctId":"NCT03668847","phase":"PHASE2","title":"DM-CHOC-PEN for Brain Tumors in AYA Subjects","status":"COMPLETED","sponsor":"DEKK-TEC, Inc.","startDate":"2019-01-01","conditions":"Advanced Cancer, Brain Metastases","enrollment":20},{"nctId":"NCT03371004","phase":"PHASE1","title":"DM-CHOC-PEN Plus Radiation for Brain Tumors","status":"COMPLETED","sponsor":"DEKK-TEC, Inc.","startDate":"2016-02-05","conditions":"Advanced Cancer","enrollment":19},{"nctId":"NCT02038218","phase":"PHASE2","title":"Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome (DM-CHOC-PEN) in Patients With Brain Tumors","status":"COMPLETED","sponsor":"DEKK-TEC, Inc.","startDate":"2013-09","conditions":"Primary Brain Tumors, Metastatic Malignant Neoplasm to Brain","enrollment":29},{"nctId":"NCT02889445","phase":"","title":"A Phase I Trial of DM-CHOC-PEN in Adolescent and Young Adult (AYA) Subjects With Advanced Cancers","status":"NO_LONGER_AVAILABLE","sponsor":"DEKK-TEC, Inc.","startDate":"","conditions":"Advanced Cancer","enrollment":""},{"nctId":"NCT01048008","phase":"PHASE1","title":"Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer","status":"COMPLETED","sponsor":"DEKK-TEC, Inc.","startDate":"2010-09","conditions":"Advanced Cancer, Brain Involvement","enrollment":22},{"nctId":"NCT01976910","phase":"PHASE1","title":"Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer\"","status":"COMPLETED","sponsor":"DEKK-TEC, Inc.","startDate":"2010-09","conditions":"Advanced Cancer","enrollment":23}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DM-CHOC-PEN"],"phase":"phase_2","status":"active","brandName":"4-Demethyl-4-cholestryloxycarbonylpenclomedine","genericName":"4-Demethyl-4-cholestryloxycarbonylpenclomedine","companyName":"DEKK-TEC, Inc.","companyId":"dekk-tec-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"4-Demethyl-4-cholestryloxycarbonylpenclomedine is a chemotherapy medication that works by inhibiting the enzyme topoisomerase II. Used for Metastatic breast cancer, Metastatic ovarian cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}